Metachronous development of breast and prostate cancer (case report)
M. G. Gordiev,
M. O. Druzhkov,
A. Yu. Dulesova,
A. G. Nikitin,
M. Yu. Ulyanin,
E. V. Platonova,
O. I. Brovkina https://doi.org/10.17650/1726-9776-2021-17-4-151-156
Abstract
The formation of primary multiple malignant neoplasms, such as breast cancer and prostate cancer, in one patient is a rather rare combination. Treatment and diagnostic strategies in such cases require a multidisciplinary approach. Currently, there are no approved recommendations for the management of patients with a combination of these diseases. This manuscript presents a clinical case of diagnosis and treatment of breast and prostate cancer in one patient.
Keywords
prostate cancer,
hereditary breast and ovarian cancer syndrome,
BRCA2 mutation,
next generation sequencing,
genetic diagnosis
Supporting agencies: The work was performed with the support of the Russian Science Foundation grant No. 21-75-00041 (https://rscf.ru/project/21-75-00041/).
About the Authors
M. G. Gordiev
Medical Diagnostic Center, Medical Institute named after Berezin Sergey
Russian Federation
Competing Interests:
Russian Federation
Build. 3A, 2 Yesenina St., Saint-Petersburg 194354.
Competing Interests:
The authors declare no conflict of interest.
M. O. Druzhkov
Druzhkov's Clinic
Russian Federation
Competing Interests:
Russian Federation
31 Sibgata Khakima St., Kazan 420126.
Competing Interests:
The authors declare no conflict of interest.
A. Yu. Dulesova
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Tatarstan
Russian Federation
Competing Interests:
Russian Federation
29 Sibirskiy Trakt St., Kazan 420029.
Competing Interests:
The authors declare no conflict of interest.
A. G. Nikitin
Federal Scientific and Clinical Center for Specialized Types of Medical Aid and Medical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
28 Orekhovyy Bul'var, Moscow 115682.
Competing Interests:
The authors declare no conflict of interest.
M. Yu. Ulyanin
Republican Clinical Hospital, Ministry of Health of the Republic of Tatarstan; Kazan (Volga Region) Federal University
Russian Federation
Competing Interests:
Russian Federation
138 Orenburgskiy Trakt St., Kazan 420064; 18 Kremlevskaya St., Kazan 420008.
Competing Interests:
The authors declare no conflict of interest.
E. V. Platonova
Reedsense Genomic Center
Russian Federation
Competing Interests:
Russian Federation
2B Promyshlennaya St., Troitsk, Moscow 142190.
Competing Interests:
The authors declare no conflict of interest.
O. I. Brovkina
Federal Scientific and Clinical Center for Specialized Types of Medical Aid and Medical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Competing Interests:
Russian Federation
Ol'ga I. Brovkina.
28 Orekhovyy Bul'var, Moscow 115682.
Competing Interests:
The authors declare no conflict of interest.
References
1. Axel E.M., Matveev V.B. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Onkourologiya = Cancer Urology 2019;15(2):15-24. (In Russ.). DOI: 10.17650/1726-97762019-15-2-15-24.
2. Konduri S., Singh M., Bobustuc G. et al. Epidemiology of male breast cancer. Breast 2020;54:8-14. DOI: 10.1016/j.breast.2020.08.010.
3. Hemminki K., Forsti A., Chen B. Breast and prostate cancer: familial associations. Nat Rev Cancer 2010;10(7):523. DOI: 10.1038/nrc2795-c1.
4. Fedier A., Fink D. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review). Int J Oncol 2004;24(4):1039-47.
5. Risbridger G.P., Davis I.D., Birrell S.N., Tilley W.D. Breast and prostate cancer: more similar than different. Nat Rev Cancer 2010;10(3):205-12. DOI: 10.1038/nrc2795.
6. Ferla R., Calo V., Cascio S. et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007;18 Suppl 6:vi93-8. DOI: 10.1093/annonc/mdm234.
7. Fackenthal J.D., Olopade O.I. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7(12):937-48. DOI: 10.1038/nrc2054.
8. Stone L. The IMPACT of BRCA2 in prostate cancer. Nat Rev Urol 2019;16(11):639. DOI: 10.1038/s41585-019-0249-4.
9. Messina C., Cattrini C., Soldato D. et al. BRCA mutations in prostate cancer: prognostic and predictive implications. J Oncol 2020;2020:4986365. DOI: 10.1155/2020/4986365.
10. Castro E., Goh C., Olmos D. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31(14):1748-57. DOI: 10.1200/JCO.2012.43.1882.
11. Matveev V., Lyubchenko L., Kirichek A. Impact of germline DNA-repair gene BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-naive prostate cancer: a single center analysis. J Clin Oncol 2019;37:5056. DOI: 10.1200/JCO.2019.37.15_suppl.5056.
12. Matveev V.B., Kirichek A.A., Filippova M.G. et al. Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-naive prostate cancer. Urologiya = Urologiia 2019;(5):79-85. (In Russ.). DOI: 10.18565/urology.2019.5.79-85.
Review
For citations:
Gordiev M.G., Druzhkov M.O., Dulesova A.Yu., Nikitin A.G., Ulyanin M.Yu., Platonova E.V., Brovkina O.I. Metachronous development of breast and prostate cancer (case report). Cancer Urology. 2021;17(4):151-156. (In Russ.) https://doi.org/10.17650/1726-9776-2021-17-4-151-156
Views:
655
Email this article 